Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00144300 · ClinicalTrials.gov registry record · Phase 4
Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients
A Phase 4 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 4
- Development phase
- 246
- Enrollment target
NCT00144300 is a Phase 4 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 246 participants.
The verdict
NCT00144300, a Phase 4 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 246 participants
- Enrollment target
Study Summary
To determine if there is any difference in the presence of retinal deterioration in PD patients treated with pramipexole IR versus ropinirole as monitored by comprehensive ophthalmologic assessments from baseline to the end of study at two years.
Interventions
- DRUG Mirapex
- DRUG Requip
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 246 participants |
| Start Date | 2005-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00144300
The ClinicalTrials.gov registry entry for NCT00144300 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 246 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Mirapex is the first listed.
NCT00144300 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00144300 about?
NCT00144300 is a clinical study titled "Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients". To determine if there is any difference in the presence of retinal deterioration in PD patients treated with pramipexole IR versus ropinirole as monitored by comprehensive ophthalmologic assessments from baseline to the end of study at two years.
What is the current status of trial NCT00144300?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 246 participants. The study started on 2005-01.
What interventions are being tested in trial NCT00144300?
The interventions under investigation include: Mirapex (DRUG), Requip (DRUG).
Who is sponsoring clinical trial NCT00144300?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.